Trial · NCT07401433
Levetiracetam Versus Phenobarbitone for the Treatment of Neonatal Seizures in a Tertiary Care Hospital.
NCT07401433, Not applicable, Completed, Hayat Abad Medical Complex, Peshawar
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Levetiracetam Versus Phenobarbitone for the Treatment of Neonatal Seizures in a Tertiary Care Hospital. Trials, record NCT07401433. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07401433
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Levetiracetam Versus Phenobarbitone for the Treatment of Neonatal Seizures in a Tertiary Care Hospital.
- NCT number
- NCT07401433
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 260 participants, actual
- Lead sponsor
- Hayat Abad Medical Complex, Peshawar
- Conditions
- Neonatal Seizures
- Interventions
- Levetiracetam, Phenobarbital Sodium Injection
- First posted
- 2026-02-10
- Last updated
- 2026-02-10
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Seizure Cessation Within 40 Minutes | Immediately after first-line drug administration (within 40 minutes) | Proportion of neonates with clinically diagnosed seizures whose seizures stopped completely within 40 minutes after administration of the first-line anticonvulsant. |
| Secondary | Time to Seizure Cessation | From first-line drug administration to seizure cessation (up to 40 minutes) | Time duration from administration of the first dose to complete cessation of seizures. |
| Secondary | Need for Second-Line Anticonvulsant | Immediately after first-line treatment failure (within 40 minutes of initial drug administration) | Proportion of neonates requiring second-line anticonvulsant therapy due to failure of initial treatment. |
| Secondary | Seizure Recurrence During Hospital Stay | From initial seizure control through 7 days of hospitalization | Number of neonates who develop recurrent seizures after initial control during the hospital stay. |
| Secondary | Incidence of Adverse Drug Reactions | From first drug administration through the first 5 days of hospitalization | Incidence of adverse effects (e.g., sedation, hypotension, respiratory depression, rash, feeding intolerance) associated with levetiracetam or phenobarbitone. |
| Secondary | Mortality | From enrollment through assessment at discharge, 28 days and 90days | Number of deaths occurring during hospital stay among neonates treated with levetiracetam or phenobarbitone. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07401433
GET https://conductscience.org/api/trials/v1/NCT07401433/registered